10.2217/14750708.2.3.333 © 2 part of Cytomegalovirus (CMV) continues to be an important cause of significant disease in various groups of immunocompromised hosts, including organ and hematopoietic stem cell transplant recipients and AIDS patients. Therapeutic and preventative strategies have been used in these patients to improve overall outcomes. Ganciclovir has traditionally been the first-li...

and the AUC0 – 12 was 24.5 mg.h/L. After 19 days of treatment, CMV PCR became negative. Oral valganciclovir was stopped after 4 weeks without adverse events. Along with the CMV PCR test becoming negative, proteinuria dramatically decreased, anaemia improved and digestive symptoms disappeared. At the 1 year follow-up, a CMV test was still negative and no relapse of nephrotic syndrome was noticed...

We suggest ganciclovir by IV administration be the treatment of choice for moderate-severe Cytomegalovirus (CMV) disease and patients with gastrointestinal involvement where drug absorption may be impaired. Mild CMV disease in adults may be treated with either oral valganciclovir or IV ganciclovir (Level II evidence, single study). Drug dose should be reduced in patients with renal impairment. ...

Acyclovir phosphonate [9-(3-phosphono-propyloxymethyl)guanine; SR3722] and the S enantiomer (SR3772), R enantiomer (SR3773), and R,S enantiomeric mixture (SR3745A) of ganciclovir phosphonate (9-[((+/-)-1-hydroxymethyl-3-phosphono)propyloxymethyl]guanine) were evaluated for their antiviral activities against murine cytomegalovirus. In severe combined immunodeficient mice infected with murine cyt...

Safe and effective treatments for chronic hepatitis B virus (HBV) infection have yet to be developed. Both ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) and foscarnet (trisodium phosphonoformate hexahydrate) are potent inhibitors of hepadnavirus replication when used individually in vitro and in vivo. However, the clinical usefulness of each drug is reduced by dose-limiting toxicity, e...

PURPOSE To report crystal formation as a complication of intravitreal ganciclovir injection. PATIENTS AND METHODS A 73-year-old female patient with unilateral cytomegalovirus retinitis was treated with intravitreous ganciclovir (4 mg/0.04 mL). RESULTS After the intravitreal injection, sudden crystallization was observed in the vitreous humor. The patient experienced marked reduction in visu...

We report a case of CMV corneal endotheliitis that was treated with intravitreal ganciclovir injection. A 56-year-old man who has suffered from uveitis was referred to our clinic due to corneal endothelial abnormality. Slit lamp examination showed a localized sectoral corneal edema and linear keratic precipitates along the boundary of edema. In spite of treatment with oral steroid and acyclovir...

We have previously reported that an intermittent pp65 antigenemiaguided early treatment strategy based on quantitative antigenemia was less effective in preventing cytomegalovirus (CMV) disease before day 100 than ganciclovir administered from engraftment until day 100 (ie, 14.1% v 2.7%, P 5 .002).1 We hypothesized that the high incidence of CMV disease before day 100 in the antigenemia-gancicl...

A method based on manipulation of the human cytomegalovirus genome in a bacterial artificial chromosome was developed to determine the role played by 6 UL97 mutations of unknown significance. These mutations were found in blood samples from solid-organ transplant recipients in a trial comparing valganciclovir and oral ganciclovir prophylaxis. Recombinant viruses containing UL97 mutations P405L,...